Literature DB >> 3860687

Inhibition of human tumor cell-associated fibrinolysis by vascular bovine smooth muscle cells.

W E Laug.   

Abstract

Fibrinolysis induced by human tumor cells producing either urokinase (u-PA) or tissue-type plasminogen activators (t-PA) was inhibited by growth in vitro of the tumor cells together with aortic bovine smooth muscle cells (SMC). Both types of plasminogen activators secreted by the tumor cells were partially or completely neutralized in such cocultivation experiments. The fibrinolysis inhibitory activities were found in living SMC, homogenates of the cells, and medium conditioned by the SMC. Incubation of medium conditioned by the SMC with media conditioned by the tumor cells followed by polyacrylamide gel electrophoresis and regular fibrin zymography resulted in sodium dodecyl sulfate-resistant inhibition of fibrinolysis. Gel electrophoretic analysis of medium conditioned by SMC followed by reverse fibrin autography revealed the presence of a single zone of lysis inhibition that corresponded to a relative molecular weight of 51,500 +/- 1,700. These results demonstrate that SMC produce and secrete a powerful inhibitor of u-PA- and t-PA-induced fibrinolysis, which may alter the invasive and degradative potential of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3860687

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

1.  Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.

Authors:  J F Cajot; J Bamat; G E Bergonzelli; E K Kruithof; R L Medcalf; J Testuz; B Sordat
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells.

Authors:  X H Pei; Y Nakanishi; K Takayama; F Bai; M Kawasaki; N Hara
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.